Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease

P.105 The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHDA rat model of Parkinson's disease

(2020) A. Gajos-Draus et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats

(2020) Keita Arakawa et al.   Pharmacological Reports

The Potent PDE10A Inhibitor MP-10 (PF-2545920) Suppresses Microglial Activation in LPS-Induced Neuroinflammation and MPTP-Induced Parkinson’s Disease Mouse Models

(2020) Do-Yeon Kim et al.   Journal of Neuroimmune Pharmacology

Synthesis and characterization of novel classes of PDE10A inhibitors - 1 H -1,3-benzodiazoles and imidazo[1,2- a ]pyrimidines

(2018) Rafał Moszczyński-Pętkowski et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A Selective Phosphodiesterase 10A Inhibitor Reduces L -Dopa-Induced Dyskinesias in Parkinsonian Monkeys

(2018) Goichi Beck et al.   MOVEMENT DISORDERS

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

(2018) Susan H. Fox et al.   MOVEMENT DISORDERS

Combined ipsilateral limb use score as an index of motor deficits and neurorestoration in parkinsonian rats

(2017) Juuso V. Leikas et al.   JOURNAL OF NEUROSCIENCE RESEARCH

The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats

(2017) Atsushi Nakatani et al.   NEUROSCIENCE RESEARCH

Depressive-like neurochemical and behavioral markers of Parkinson’s disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle

(2017) Kinga Kamińska et al.   Pharmacological Reports

TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms

(2016) Kazunori Suzuki et al.   NEUROPSYCHOPHARMACOLOGY

Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: Comparison to the classical neurotoxin 6-OHDA

(2015) Jolanta Konieczny et al.   BEHAVIOURAL BRAIN RESEARCH

Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson’s disease

(2015) Flavia Niccolini et al.   BRAIN

Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum

(2015) Jonathan M. Wilson et al.   NEUROPHARMACOLOGY

The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents

(2015) Renee C. Gentzel et al.   NEUROPHARMACOLOGY

Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease

(2015) C. Fidalgo et al.   NEUROSCIENCE

Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?

(2014) Giuseppe Sancesario et al.   NEUROCHEMISTRY INTERNATIONAL

Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

(2014) E. Tronci et al.   NEUROSCIENCE

Chronic l-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra

(2013) Jolanta Konieczny et al.   BEHAVIOURAL BRAIN RESEARCH

Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications

(2013) Subramaniam Uthayathas et al.   NEUROPHARMACOLOGY

Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions

(2013) Dalila Mango et al.   NEUROPHARMACOLOGY

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

(2012) Sean M. Smith et al.   NEUROPHARMACOLOGY

PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: A key step in parkinsonism physiopathology

(2011) M. Giorgi et al.   NEUROBIOLOGY OF DISEASE

Neurotoxin-based models of Parkinson's disease

(2011) J. Bové et al.   NEUROSCIENCE

A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug

(2009) Annalisa Pinna et al.   NEUROPHARMACOLOGY

Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A

(2009) Christine A. Strick et al.   NEUROPHARMACOLOGY

Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms

(2008) M. Giorgi et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum

(2008) A. Nishi et al.   JOURNAL OF NEUROSCIENCE

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

(2008) S. Threlfell et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

(2008) C. J. Schmidt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS